Aytu Biopharma (AYTU) Other Non-Current Liabilities (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Other Non-Current Liabilities data on file, last reported at $4.8 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 17.41% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 17.41% increase from a year earlier, with the FY2025 full-year figure at $4.9 million, up 8.59% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $4.8 million, down from $27.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for AYTU reached as high as $27.3 million in Q4 2025 and fell as low as $1.6 million in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $7.3 million across 5 years, with a median of $5.6 million in 2022.
• Across the five-year window, Other Non-Current Liabilities jumped 1646.61% in 2022 and sank 71.63% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $9.8 million in 2022, then plunged by 35.14% to $6.3 million in 2023, then gained by 0.66% to $6.4 million in 2024, then surged by 328.08% to $27.3 million in 2025, then slumped by 82.28% to $4.8 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $4.8 million in Q1 2026, $27.3 million in Q4 2025, and $5.0 million in Q3 2025.